Category: Latest News

  • Vanda Pharmaceuticals Jumps After FDA Grants Orphan Drug Status for PV Therapy

    Vanda Pharmaceuticals Jumps After FDA Grants Orphan Drug Status for PV Therapy

    Vanda Pharmaceuticals (NASDAQ:VNDA) shares climbed 6% after the company revealed that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to its investigational therapy VGT-1849B for the treatment of polycythemia vera (PV). VGT-1849B is a selective peptide nucleic acid-based JAK2 inhibitor aimed at treating PV, a chronic blood disorder that affects roughly…

  • Bath & Body Works Stock Slips After Weak Q3 Guidance

    Bath & Body Works Stock Slips After Weak Q3 Guidance

    Bath & Body Works, Inc. (NYSE:BBWI) reported second-quarter results on Thursday that met revenue expectations but missed slightly on earnings, sending its shares down 1.68% in premarket trading. The retailer, known for its home fragrance and personal care products, posted adjusted EPS of $0.37—just below analysts’ consensus of $0.38. Revenue came in at $1.55 billion,…

  • Dollar General Stock Jumps as Strong Q2 Results Prompt Higher Outlook

    Dollar General Stock Jumps as Strong Q2 Results Prompt Higher Outlook

    Dollar General (NYSE:DG) shares surged in premarket trading Thursday after the discount retailer reported second-quarter earnings that beat Wall Street estimates and raised its full-year guidance. The stock was up nearly 9% at 06:59 ET. For the quarter, the company posted earnings per share of $1.86, well ahead of the $1.57 consensus estimate. Revenue came…

  • Titan Machinery Beats Q2 Forecasts While Managing Weak Demand

    Titan Machinery Beats Q2 Forecasts While Managing Weak Demand

    Titan Machinery Inc. (NASDAQ:TITN) posted second-quarter results on Thursday that came in ahead of analyst expectations, as the farm and construction equipment dealer continued working through a difficult market while advancing its inventory reduction strategy. The company reported a net loss of $0.26 per share, narrower than the projected $0.48 per share loss. Revenue reached…

  • Burlington Stores Stock Surges on Earnings Beat and Upgraded Outlook

    Burlington Stores Stock Surges on Earnings Beat and Upgraded Outlook

    Burlington Stores, Inc. (NYSE:BURL) shares climbed 7% on Thursday after the off-price retailer delivered second-quarter results that blew past Wall Street expectations and lifted its full-year earnings forecast. The company reported adjusted earnings of $1.72 per share, well above analysts’ estimates of $1.29. Revenue rose 10% year-over-year to $2.71 billion, topping the consensus forecast of…

  • Hormel Foods Shares Sink After Earnings Miss Despite Revenue Beat

    Hormel Foods Shares Sink After Earnings Miss Despite Revenue Beat

    Hormel Foods Corporation (NYSE:HRL) saw its stock drop sharply on Thursday after the company reported fiscal third-quarter earnings that fell well below analyst forecasts, overshadowing stronger-than-expected sales. Shares of the global packaged food maker slid 7.8% in premarket trading following the announcement. For the quarter ended July, Hormel posted adjusted earnings of $0.35 per share,…

  • GMS Reports Q1 Results in Line with Forecasts Amid Slight Revenue Drop

    GMS Reports Q1 Results in Line with Forecasts Amid Slight Revenue Drop

    GMS Inc. (NYSE:GMS) released its first-quarter fiscal 2026 results on Thursday, showing performance consistent with analyst expectations despite a modest decline in revenue. Shares of the North American specialty building products distributor fell slightly by 0.06% following the earnings release. The company posted adjusted earnings of $1.76 per share for the quarter ending July 31,…

  • GSK Gains U.K. Approval for Innovative Oral Antibiotic for UTIs

    GSK Gains U.K. Approval for Innovative Oral Antibiotic for UTIs

    GSK plc (NYSE:GSK) has secured approval in the U.K. for its oral antibiotic aimed at treating uncomplicated urinary tract infections (UTIs), marking the first new oral therapy for this condition in almost 30 years. The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared gepotidacin, marketed as Blujepa, for use in females aged 12 years…

  • CrowdStrike Shares Drop Despite Strong Q2 Results on Soft Q3 Revenue Outlook

    CrowdStrike Shares Drop Despite Strong Q2 Results on Soft Q3 Revenue Outlook

    CrowdStrike (NASDAQ:CRWD) posted better-than-expected results for the second quarter of fiscal 2026, but its shares fell 3% in premarket trading Thursday after the company provided third-quarter revenue guidance below analyst forecasts. For the quarter ending July 31, CrowdStrike reported adjusted earnings of $0.93 per share, surpassing the consensus estimate of $0.83. Revenue reached $1.17 billion,…

  • HP Surpasses Q3 Expectations on AI-Driven PC Demand; Q4 Outlook in Line, Shares Dip

    HP Surpasses Q3 Expectations on AI-Driven PC Demand; Q4 Outlook in Line, Shares Dip

    HP Inc (NYSE:HPQ) reported fiscal third-quarter results that exceeded analyst expectations for both earnings and revenue, while its guidance for the current quarter came roughly in line with market estimates. Despite the beat, HP shares fell more than 2% in premarket trading Thursday. For Q3, adjusted earnings per share reached $0.75, slightly above the consensus…